05.04.2021 | Published by bit.bio
Q&A with Dr Mark Kotter: Transforming drug discovery & medical research
bit.bio CEO and founder Dr Mark Kotter explains breakthrough technology opti-ox™ in this Q&A in the current edition of International Biopharmaceutical Industry Journal.
“ bit.bio develops capabilities to produce every human cell type at scale. We believe this will transform the biotech and medicine research landscape and enable a new generation of cell therapies. Synthetic biology for us is essentially the transition of biology as we know it to engineering and that’s the approach we are taking to cells."
Mark Kotter
CEO and founder, bit.bio
"bit.bio cells address this demand. These cells are physiologically relevant and phenotypically characterised, and for the first time, available at scale, offering predictive in vitro cells for drug screening.”
Mark Kotter
CEO and founder, bit.bio